Detection of proneural/mesenchymal marker expression in glioblastoma: temporospatial dynamics and association with chromatin-modifying gene expression.

Authors:
Hideki Murata
Hideki Murata
Shizuoka Cancer Center Hospital
Japan
Koji Yoshimoto
Koji Yoshimoto
Kyushu University
Japan
Ryusuke Hatae
Ryusuke Hatae
National Hospital Organization
Japan
Yojiro Akagi
Yojiro Akagi
Graduate School of Medical Sciences
Japan
Masahiro Mizoguchi
Masahiro Mizoguchi
Graduate School of Medical Sciences
Nobuhiro Hata
Nobuhiro Hata
Kyushu University
Japan
Daisuke Kuga
Daisuke Kuga
Graduate School of Medical Sciences
Akira Nakamizo
Akira Nakamizo
Graduate School of Medical Sciences

J Neurooncol 2015 Oct 14;125(1):33-41. Epub 2015 Aug 14.

Department of Neurosurgery, Graduate School of Medical Sciences, Kyushu University, 3-1-1 Maidashi, Higashi-Ku, Fukuoka, 812-8582, Japan.

Proneural and mesenchymal are two subtypes of glioblastoma identified by gene expression profiling. In this study, the primary aim was to detect markers to develop a clinically applicable method for distinguishing proneural and mesenchymal glioblastoma. The secondary aims were to investigate the temporospatial dynamics of these markers and to explore the association between these markers and the expression of chromatin-modifying genes. One hundred thirty-three glioma samples (grade II: 14 samples, grade III: 18, grade IV: 101) were analyzed. We quantified the expression of 6 signature genes associated with proneural and mesenchymal glioblastoma by quantitative reverse transcription-polymerase chain reaction. We assigned proneural (PN) and mesenchymal (MES) scores based on the average of the 6 markers and calculated a predominant metagene (P-M) score by subtracting the MES from the PN score. We used these scores to analyze correlations with malignant transformation, tumor recurrence, tumor heterogeneity, chromatin-modifying gene expression, and HDAC7 expression. The MES score positively correlated with tumor grade, whereas the PN score did not. The P-M score was able to distinguish the proneural and mesenchymal subtypes. It was decreased in cases of tumor recurrence and malignant transformation and showed variability within a tumor, suggesting intratumoral heterogeneity. The PN score correlated with the expression of multiple histone-modifying genes, whereas the MES score was associated only with HDAC7 expression. Thus, we demonstrated a simple and straightforward method of quantifying proneural/mesenchymal markers in glioblastoma. Of note, HDAC7 expression might be a novel therapeutic target in glioblastoma treatment.

Download full-text PDF

Source
http://link.springer.com/content/pdf/10.1007/s11060-015-1886
Web SearchFound
http://link.springer.com/10.1007/s11060-015-1886-y
Publisher SiteFound
http://dx.doi.org/10.1007/s11060-015-1886-yDOI Listing
October 2015
6 Reads

Publication Analysis

Top Keywords

proneural mesenchymal
20
mes score
12
hdac7 expression
12
gene expression
12
expression
10
samples grade
8
p-m score
8
malignant transformation
8
mesenchymal glioblastoma
8
tumor recurrence
8
chromatin-modifying gene
8
mesenchymal subtypes
8
temporospatial dynamics
8
score
7
glioblastoma
6
mesenchymal
5
markers
5
tumor
5
proneural
5
transformation tumor
4

Similar Publications

Associations between microRNA expression and mesenchymal marker gene expression in glioblastoma.

Neuro Oncol 2012 Sep 27;14(9):1153-62. Epub 2012 Jul 27.

Department of Neurosurgery, Graduate School of Medical Sciences, Kyushu University, Fukuoka, Japan.

The subclassification of glioblastoma (GBM) into clinically relevant subtypes using microRNA (miRNA)- and messenger RNA (mRNA)-based integrated analysis has been attempted. Because miRNAs regulate multiple gene-signaling pathways, understanding miRNA-mRNA interactions is a prerequisite for understanding glioma biology. However, such associations have not been thoroughly examined using high-throughput integrated analysis. Read More

View Article
September 2012

Coexpression analysis of CD133 and CD44 identifies proneural and mesenchymal subtypes of glioblastoma multiforme.

Oncotarget 2015 Mar;6(8):6267-80

Department of Pathology, University of Melbourne, Melbourne, Australia.

Accumulating evidence suggests that the stem cell markers CD133 and CD44 indicate molecular subtype in Glioblastoma Multiforme (GBM). Gene coexpression analysis of The Cancer Genome Atlas GBM dataset was undertaken to compare markers of the Glioblastoma Stem-Progenitor Cell (GSPC) phenotype. Pearson correlation identified genes coexpressed with stem cell markers, which were then used to build a gene signature that classifies patients based on a CD133 coexpression module signature (CD133-M) or CD44-M subtype. Read More

View Article
March 2015

Molecular heterogeneity of glioblastomas: does location matter?

Oncotarget 2016 Jan;7(1):902-13

Aix-Marseille University, CRO2 UMR 911, Inserm UMR_S 911, Marseille, 13385, France.

Glioblastomas in adults are highly heterogeneous tumors that can develop throughout the brain. To date no predictive-location marker has been identified. We previously derived two glioblastoma cell lines from cortical and periventricular locations and demonstrated distinct transcriptomic profiles. Read More

View Article
January 2016

Phospholipase C Beta 1: a Candidate Signature Gene for Proneural Subtype High-Grade Glioma.

Mol Neurobiol 2016 11 28;53(9):6511-6525. Epub 2015 Nov 28.

The Vivian L. Smith Department of Neurosurgery, The University of Texas Health Science Center at Houston (UTHealth) Medical School, 6400 Fannin Street, Suite 2800, Houston, TX, 77030, USA.

Phospholipase C beta 1 (PLCβ1) expresses in gliomas and cultured glial cells, but its expression is barely detectable in normal glial cells. We analyzed data from Gene Expression Omnibus (GEO-GDSxxx), The Cancer Genome Atlas (TCGA), and the Repository for Molecular Brain Neoplasia Data (REMBRANDT) to explore the potential role of PLCβ1 as a biomarker in high-grade glioma (HGG). PLCβ1 expression is significantly higher in grade III gliomas than that in grade IV gliomas from GDS1815 (n = 24 vs. Read More

View Article
November 2016